Abstract WP234: Mitochondria Therapy Mitigates Neuroinflammation And Provides Neuroprotection Against Ischemic Stroke In Mice

Abstract

Background: Ischemic stroke is the second prevalent life-threat problem associated with long-lasting neurological disabilities and a high mortality rate worldwide. Despite this, therapeutic options remain limited. Recently, mitochondria transplantation therapy has emerged as a potential approach for increasing brain protection. This study aimed to investigate the protective role of mitochondria transplantation against ischemic stroke-induced behavioral deficits and molecular alterations in a photothrombotic stroke model. Methods: Ischemic stroke was induced by a Rose Bengal photothrombosis method in young adult C57BL/6 mice. Repeated doses of isolated liver mitochondria (100μg/mouse) were administrated intranasally at 1 h, 3 h, 24 h, and 48 h post-stroke. After 72 h, mice were tested for behavioral outcomes and euthanized, and tissues were harvested to measure infarct volume, brain edema, and molecular analysis. Results: Mitochondria-treated mice showed a significant improvement in behavioral outcomes, reduction in infarct size, and brain edema compared to the vehicle-treated group. Additionally, mitochondria significantly inhibited the protein expression of NOD-like receptor protein-3, phospho-nuclear factor kappa-B, cleaved-interleukin-1β, apoptosis-associated speck-like protein, glial fibrillary acidic protein, and ionized calcium-binding adapter molecule-1 proteins. Furthermore, mitochondria treatment showed a lower expression of nitrotyrosine, and 4-hydroxynonenal and higher expression of endothelial nitric oxide synthase and sulfotransferase-4A1 proteins, oxidative stress markers ( Table 1 ). Conclusion: Taken together, these data indicate that mitochondria reveal neuroprotection through the attenuation of inflammation against stroke. Further investigations into the role of neuroprotection of mitochondria transplantation are needed to determine whether it can be an effective therapy for stroke patients.